Nektar Therapeutics Corp.
- BID
60
- ASK
61.44
- 333 Units326 Units
- 07/22, 12:19:15 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
184.76%
Market Cap
120.81 Mil.
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-8.62 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 60.02 G | 0 Units |
| PRICE DETERMINATION TIME | 07/22/2026 / 12:18:32 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 60.02 | 59.62 |
| PREV. DAY'S PRICE | 59.8 | (07/21) |
| CHANGE DAY BEFORE | +0.22 | 0.37 % |
| 52 WEEK HIGH / LOW | 87.52 (04/21) | 18.9 (08/01) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -20.16 | -8.02 | -8.62 | -7.97 | -10.00 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 0.83 | 2.84 | 9.59 | - | - |
PRICE - SALES RATIO | 1.19 | 1.94 | 12.91 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A419UB |
| ISIN | US6402683063 |
| SYMBOL | ITH0 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Nektar Therapeutics |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 183.62 Mil. |
| MARKET CAPITALISATION | 120.81 Mil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 1.74 % | 10.70 % | -31.66 % | 90.45 % | 184.76 % | 697.01 % | -71.85 % | 67.98 % |
| HIGH | 59.80 | 67.30 | 84.76 | 87.52 | 87.52 | 130.50 | 246.60 | 87.52 |
| LOW | 55.78 | 52.78 | 46.98 | 28.20 | 18.90 | 5.85 | 5.85 | 28.20 |
Dividende
pro Aktie
Nektar Therapeutics does not deliver dividend information
Company profile
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.
Structured products for Nektar Therapeutics Corp.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.